Safety analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer

被引：0
|
作者：
Taniguchi, H. [1 ]
Kito, Y. [2 ]
Satake, H. [3 ]
Horie, Y. [4 ]
Yamada, T. [5 ]
Esaki, T. [6 ]
Denda, T. [7 ]
Mori, K. [8 ]
Yamazaki, K. [9 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[2] Ishikawa Prefectural Cent Hosp, Dept Med Oncol, Kanazawa, Ishikawa, Japan
[3] Gen Hosp, Kobe City Med Ctr, Dept Med Oncol, Kobe, Hyogo, Japan
[4] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Kanagawa, Japan
[5] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki, Japan
[6] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan
[7] Chiba Canc Ctr Hosp, Div Gastroenterol, Chiba, Japan
[8] Shizuoka Canc Ctr, Clin Res Ctr, Shizuoka, Japan
[9] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
530P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Update analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
    Yamada, T.
    Kito, Y.
    Satake, H.
    Taniguchi, H.
    Horie, Y.
    Esaki, T.
    Denda, T.
    Mori, K.
    Yamazaki, K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [2] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    Kito, Yosuke
    Satake, Hironaga
    Taniguchi, Hiroya
    Yamada, Takeshi
    Horie, Yoshiki
    Esaki, Taito
    Denda, Tadamichi
    Yasui, Hisateru
    Izawa, Naoki
    Masuishi, Toshiki
    Moriwaki, Toshikazu
    Mori, Keita
    Yamazaki, Kentaro
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 277 - 284
  • [3] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    Yosuke Kito
    Hironaga Satake
    Hiroya Taniguchi
    Takeshi Yamada
    Yoshiki Horie
    Taito Esaki
    Tadamichi Denda
    Hisateru Yasui
    Naoki Izawa
    Toshiki Masuishi
    Toshikazu Moriwaki
    Keita Mori
    Kentaro Yamazaki
    [J]. Cancer Chemotherapy and Pharmacology, 2020, 86 : 277 - 284
  • [4] Dose finding phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer: The initial safety analysis
    Hironaga, Satake
    Yosuke, Kito
    Hiroya, Taniguchi
    Yoshiki, Horie
    Takeshi, Yamada
    Taito, Esaki
    Tadamichi, Denda
    Keita, Mori
    Kentaro, Yamazaki
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [5] Dose-finding phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
    Yamazaki, K.
    Kito, Y.
    Esaki, T.
    Satake, H.
    Taniguchi, H.
    Tsuda, T.
    Denda, T.
    Moriwaki, T.
    Mori, K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
    Oki, Eiji
    Kato, Takeshi
    Bando, Hideaki
    Yoshino, Takayuki
    Muro, Kei
    Taniguchi, Hiroya
    Kagawa, Yoshinori
    Yamazaki, Kentaro
    Yamaguchi, Tatsuro
    Tsuji, Akihito
    Iwamoto, Shigeyoshi
    Nakayama, Goro
    Emi, Yasunori
    Touyama, Tetsuo
    Nakamura, Masato
    Kotaka, Masahito
    Sakisaka, Hideki
    Yamanaka, Takeharu
    Kanazawa, Akiyoshi
    [J]. CLINICAL COLORECTAL CANCER, 2018, 17 (02) : 147 - 155
  • [7] Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
    Kito, Y.
    Yamazaki, K.
    Shoji, H.
    Yamada, T.
    Tsushima, T.
    Mitani, S.
    Shiraishi, K.
    Yasui, H.
    Hara, H.
    Shimozaki, K.
    Esaki, T.
    Shimokawa, H.
    Kajiura, S.
    Masuishi, T.
    Baba, E.
    Yoshimura, K.
    Kawakami, H.
    Hironaka, S.
    Muro, K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S715 - S715
  • [8] Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
    Nipp, Ryan D.
    Ryan, David P.
    [J]. ONCOLOGIST, 2015, 20 (03): : 236 - 238
  • [9] The safety and efficacy of FOLFOXIRI plus molecular target therapy as a first-line treatment for metastatic colorectal cancer: A multicentre retrospective study
    Ogata, T.
    Satake, H.
    Ogata, M.
    Hatachi, Y.
    Hamada, M.
    Yasui, H.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [10] Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study
    Yamada, T.
    Kito, Y.
    Sakai, K.
    Nishio, K.
    Yamazaki, K.
    Shoji, H.
    Tsushima, T.
    Mitani, S.
    Shiraishi, K.
    Yasui, H.
    Hara, H.
    Shimozaki, K.
    Esaki, T.
    Shimokawa, H.
    Tsuzuki, T.
    Kajiura, S.
    Masuishi, T.
    Baba, E.
    Yoshimura, K.
    Kawakami, H.
    Hironaka, S.
    Muro, K.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S42 - S42
12345